Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Defactinib (Primary)
- Indications Malignant-mesothelioma
- Focus Registrational; Therapeutic Use
- Acronyms COMMAND
- Sponsors Verastem Oncology
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 04/12/2015, according to European Clinical Trials Database record.
- 20 Feb 2019 Results published in the Journal of Clinical Oncology
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.